Merck & Co. Inc.
PO Box 100
One Merck Drive
Whitehouse Station,
NJ 08889-0100
United States - Map
Phone: 908-423-1000
Fax: 908-735-1253
Web Site: http://www.merck.com
| Merck & Co., Inc. provides products for human and animal health in the United States and internationally. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Zocor, an atherosclerosis product; Cosopt and Trusopt, the ophthalmological products; Primaxin and Cancidas, the anti bacterial/anti fungal products; Januvia and Janumet for type 2 diabetes; Maxalt, an acute migraine product; Proscar to treat symptomatic benign prostate enlargement; Propecia for the treatment of male pattern hair loss; Arcoxia to treat arthritis and pain; Crixivan and Stocrin for the treatment of HIV infection; Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting; and Invanz for treating infection. Merck & Co.’s Vaccines segment comprises human health vaccine products, such as preventative pediatric, adolescent, and adult vaccines administered at physician offices. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; RotaTeq to protect against rotavirus gastroenteritis in infants and children; Zostavax for preventing shingles; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; and M-M-R II, a vaccine against measles, mumps, and rubella. Merck & Co. has agreements with Neuromed Pharmaceuticals, Ltd., FoxHollow Technologies, Inc., Ariad Pharmaceuticals, Inc., Dynavax Technologies Corp., and GTX, Inc, as well as collaboration with Metabasis Therapeutics, Inc. and Idera Pharmaceuticals, Inc. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Richard T. Clark , 62
Exec. Chairman, Chief Exec. Officer and Pres |
$
5.93M |
$
114.00K | Mr. Peter N. Kellogg , 51
Chief Financial Officer and Exec. VP |
$
911.00K | N/A | Mr. Kenneth C. Frazier , 53
Exec. VP and Pres of Global Human Health |
N/A
| N/A | Dr. Peter S. Kim Ph.D., 49
Exec. VP and Pres of Merck Research Laboratories |
N/A
| N/A | Ms. Margaret G. McGlynn , 48
Pres of Merck Vaccines |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
6.54% Nasdaq 
Profile
